Zacks Investment Research downgraded shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) from a hold rating to a sell rating in a research note released on Wednesday morning.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other research firms have also recently weighed in on ENTA. Robert W. Baird boosted their target price on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a neutral rating in a research note on Tuesday, August 8th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, August 11th. J P Morgan Chase & Co reiterated an overweight rating and issued a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. JMP Securities boosted their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday. Finally, Royal Bank Of Canada started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, September 14th. They issued an outperform rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of Hold and an average price target of $42.33.

Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.08% on Wednesday, reaching $48.60. 181,899 shares of the company’s stock traded hands. The stock’s market cap is $927.77 million. Enanta Pharmaceuticals has a 52-week low of $22.17 and a 52-week high of $48.80. The company’s 50 day moving average is $43.57 and its 200-day moving average is $36.17.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company’s quarterly revenue was down 46.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) earnings per share. Equities analysts expect that Enanta Pharmaceuticals will post $1.14 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/zacks-investment-research-lowers-enanta-pharmaceuticals-inc-enta-to-sell/1615497.html.

Several hedge funds and other institutional investors have recently bought and sold shares of ENTA. Mason Street Advisors LLC raised its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 212 shares during the period. GAM Holding AG bought a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $108,000. Municipal Employees Retirement System of Michigan raised its position in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 110 shares during the period. SG Americas Securities LLC raised its position in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares during the period. 66.07% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.